News

Latest UK Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Showing 1–24 of 113 updates
Company News5 Nov 2026
Resolution Therapeutics

Resolution Therapeutics Reports Positive Interim EMERALD Data for RTX001 in Liver Disease

Resolution Therapeutics has reported six-month interim Phase I/II EMERALD data for RTX001, an engineered macrophage therapy for end-stage liver disease. Against an external control, the first nine patients showed a 42% relative risk reduction in death, liver transplant or hepatic decompensation. The company plans a pivotal US trial, with a pre-IND meeting with the FDA scheduled for December 2026.
Company News5 Nov 2026
Link Biologics

Link Biologics Completes IND-Enabling Studies for Dry Eye Drug LB001

Link Biologics has completed the IND-enabling preclinical programme for LB001, a TSG-6-based eye drop for moderate to severe dry eye disease. Repeat-dose ocular toxicology studies of up to 13 weeks showed favourable tolerability, and two GMP runs will supply the planned Phase 1/2 study. The IND submission remains on track for Q1 2027.
Company News3 Nov 2026
OGT

OGT Adds Four IVDR-Certified CytoCell FISH Probes for Blood Cancers

OGT has expanded its CytoCell portfolio with four fluorescence in situ hybridisation (FISH) probes newly certified under the EU In Vitro Diagnostic Regulation (IVDR). The assays, including ATM and IGH-targeting probes, were already available under the older IVDD framework and support cytogenetic assessment of haematological malignancies. Their certification forms part of OGT's staged transition ahead of the December 2028 Class C deadline.
Company News3 Nov 2026
Allergy Therapeutics

Allergy Therapeutics Proposes AIM Delisting and Private Status

Allergy Therapeutics has proposed cancelling admission of its shares to AIM and re-registering as a private limited company, citing low share liquidity, valuation concerns and listing costs. The proposal requires approval from at least 75% of votes cast at its annual general meeting. Its two major shareholders have indicated support, while the company says it will continue to explore a possible Hong Kong listing.
Company News2 Nov 2026
Sareum

Sareum Reports Narrower Annual Loss and SDC-1801 Progress

Sareum reported a pre-tax loss of £3.5 million for the year ended 30 June 2026, compared with £4.9 million a year earlier, with no revenue. In its accompanying development update, the company confirmed completion of dosing in the Phase 2-enabling toxicology programme for SDC-1801 in July. Full toxicology results are expected during the fourth quarter of 2026, with further formulation and regulatory work ongoing.
Company News2 Nov 2026
Iksuda Therapeutics

Iksuda Reports Preliminary Phase 1 IKS014 Data Ahead of SABCS

Iksuda Therapeutics reported preliminary Phase 1 findings for IKS014, its HER2-directed antibody-drug conjugate, ahead of a December scientific presentation. Among 105 treated patients, 16 experienced Grade 3 treatment-related adverse events. In a subgroup of ten response-evaluable breast cancer patients previously treated with trastuzumab deruxtecan, five had confirmed or unconfirmed partial responses. The findings are preliminary and do not establish efficacy in a larger patient population.
Company News2 Nov 2026
Tiziana Life Sciences

Tiziana Reports Phase 2a INFORM-MS Trial Meets Primary Endpoints

Tiziana Life Sciences reported that its 48-patient Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis met both primary endpoints covering PET-measured microglial activation and safety. The 50 μg group showed a statistically significant reduction in the imaging marker versus placebo after 12 weeks. The company also reported improvements in fatigue scores, although the trial was not powered to establish definitive clinical efficacy.
Company News2 Nov 2026
Qureight

Qureight Publishes Viewpoint on CT Fibrosis Biomarkers in Trials

Qureight has announced a peer-reviewed Viewpoint in the European Respiratory Journal proposing that fibrosis extent measured using quantitative high-resolution CT could complement lung-function testing in antifibrotic trials. The authors argue that imaging may capture structural disease changes more directly than forced vital capacity alone. They also state that further trial-level evidence is needed before fibrosis extent could qualify as a regulatory surrogate endpoint.
View CompanySource: Qureight
Company News30 Oct 2026
Inovia Bio

Inovia Bio Launches InovaMine Biostatistics and Reporting Software

Inovia Bio has made InovaMine available as a standalone software product for biostatistics and clinical-data reporting. The platform takes datasets and statistical analysis plans, generates tables, listings and figures, and links reported results back to source records for traceability. According to the company, statistical outputs are reviewed and signed off by a statistician before release.
View CompanySource: Inovia Bio
Company News29 Oct 2026
Tangram Therapeutics

Tangram Doses First Participant in Phase 1 Trial of ZPI-Silencing siRNA TGM-148

Tangram Therapeutics has dosed the first participant in a Phase 1 trial of TGM-148 in healthy volunteers. TGM-148 is a GalNAc-conjugated siRNA that silences protein Z-dependent protease inhibitor (ZPI), a natural regulator of coagulation, in the liver.
Company News29 Oct 2026
Bicycle Therapeutics

Bicycle Therapeutics Wins FDA Orphan Drug Status for Nuzefatide in Pancreatic Cancer

Bicycle Therapeutics disclosed with its Q3 results that the FDA granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer in September. The EphA2-targeting Bicycle Drug Conjugate is in a Phase 2 trial in recurrent pancreatic ductal adenocarcinoma, with further updates expected in 2027. The designation is a regulatory status, not an approval.
Company News29 Oct 2026
Hikma Pharmaceuticals

Hikma Launches NPH Otic Solution in US with Orbicular Partnership

Hikma Pharmaceuticals has launched a sterile generic ear-drop treatment containing neomycin, polymyxin B and hydrocortisone in the United States. The product was developed by Orbicular Pharmaceutical Technologies, which holds the abbreviated new drug application, while Hikma will commercialise and distribute it. The medicine has FDA approval as a Competitive Generic Therapy for certain bacterial infections of the external ear. The announcement does not establish UK marketing approval.
Company News28 Oct 2026
Cell Guidance Systems

Cell Guidance Systems Launches Automated EVlution Pro TFF Systems

Cell Guidance Systems has launched EVlution Pro, a benchtop tangential-flow filtration system for concentrating and exchanging buffers in samples containing extracellular vesicles, proteins and other biomolecules. Two models are available: Pro 1 provides basic monitoring, while Pro 3 adds balances, pressure and temperature sensors with automated data logging. Orders are open. The launch extends its existing EVlution cartridge range rather than introducing filtration technology for the first time.
Company News27 Oct 2026
Purespring Therapeutics

Purespring Presents Preclinical PS-003 Data in X-Linked Alport Syndrome, Targets 2027 IND

Purespring Therapeutics has presented preclinical data at ASN Kidney Week 2026 showing that a single dose of its kidney-targeted gene therapy PS-003 produced durable COL4A5 expression in a mouse model of X-linked Alport syndrome, with no treatment-related safety concerns in minipigs. The company plans to file an IND in 2027.
Company News26 Oct 2026
OGT

OGT Launches First Dedicated Fusion MRD NGS Panel for AML

OGT has launched the SureSeq myPanel Myeloid Fusion MRD Panel, which it describes as the first dedicated next-generation sequencing panel for detecting AML fusion events at measurable residual disease sensitivity. The research-use panel was developed with Roswell Park Comprehensive Cancer Center and can be run alongside OGT's Myeloid MRD Plus panel.
Company News26 Oct 2026
Microbiotica

Microbiotica Presents Phase 1b MELODY-1 Data for MB097 with Keytruda in Refractory Melanoma

Microbiotica has presented Phase 1b MELODY-1 data at ESMO 2026 for MB097, its nine-strain live biotherapeutic, given with Keytruda to 41 melanoma patients who had not responded to anti-PD-1 therapy. Objective responses were seen in 14% of patients who received vancomycin preconditioning and 10% of those who did not, including one complete response, with no serious adverse events related to MB097.
Company News26 Oct 2026
Biographica

Biographica Introduces CROP-1 AI Model for Crop Gene Regulation

Biographica has introduced CROP-1, a genomic AI model combining DNA sequence and biological context to predict gene expression across crops and conditions. The company reports stronger computational prediction results than several comparison models and describes possible applications in targeted crop trait development. Its proposed regulatory edits remain predictions, not experimentally demonstrated improvements in plants. The accompanying research manuscript has not yet undergone peer review.
Company News26 Oct 2026
U-Ploid Biotechnologies

U-Ploid's LYVANTA Nearly Doubles Share of Error-Free Human Eggs in Lab Study

U-Ploid Biotechnologies has reported that its investigational therapy LYVANTA (UP-085) raised the share of chromosomally error-free human eggs to 65.6% from 35.7% in a randomised laboratory study using eggs donated at six UK fertility clinics, presented at ASRM 2026. The results are preclinical, and safety studies and clinical trials are still needed.
Company News26 Oct 2026
Pharmanovia

Pharmanovia Presents Updated Phase 3 FLAMES Data for Senaparib in Ovarian Cancer

Pharmanovia has presented updated Phase 3 FLAMES data at ESMO 2026 showing median progression-free survival of 38.7 months with senaparib versus 13.6 months with placebo as first-line maintenance in advanced ovarian cancer (HR 0.47). Pharmanovia holds rights to senaparib across 66 countries including the EU and UK, and the drug received a positive CHMP opinion in September and awaits a European Commission decision.
Company News26 Oct 2026
Avacta Therapeutics

Avacta Reports 11.4-Month Median PFS for Faridoxorubicin in Salivary Gland Cancer at ESMO 2026

Avacta Therapeutics has reported a median progression-free survival of 11.4 months for faridoxorubicin (AVA6000) in 32 salivary gland cancer patients treated at 310 mg/m² and above in its Phase 1a/1b trial, against historical benchmarks of 6 to 6.7 months from earlier studies. The data, presented at ESMO 2026, included three partial responses, with first efficacy data for next-generation candidate AVA6103 expected in H1 2027.
Company News23 Oct 2026
Avacta Therapeutics

Avacta Presents AVA6103 Preclinical Data in Enhertu-Resistant Tumour Models at ESMO

Avacta Therapeutics has presented preclinical data at ESMO 2026 showing its FAP-targeted drug conjugate AVA6103 produced partial responses in mouse tumour models and stable disease in gastric tumours that had progressed on Enhertu. The Phase 1a FOCUS-01 trial has completed enrolment at its fourth dose level, with first efficacy data expected in H1 2027.
Company News23 Oct 2026
BioOrbit

BioOrbit Completes Six-Week ISS Mission Growing Protein Crystals for Cancer Drugs

BioOrbit has completed a six-week experiment aboard the International Space Station using its Baby BOX-E unit, which the company says achieved the largest-scale production of protein crystals in space to date. The crystals are intended for highly concentrated cancer drugs that could be self-injected at home rather than given as hospital infusions, and the mission follows BioOrbit's £9.8 million seed round in April.
View CompanySource: UKRI
Company News21 Oct 2026
Rezera

Rezera Files US IPO Registration to Support Phase 3 Ruvonoflast

Rezera, formerly NodThera, filed a Form S-1 registration statement with the US Securities and Exchange Commission on 21 October 2026 for a potential initial public offering. The company is developing NLRP3 inhibitors, including ruvonoflast, which it plans to advance into Phase 3 for peripheral artery disease. The filing does not establish that the share offering has priced, completed or begun trading.
Company News21 Oct 2026
AstraZeneca+1 company

AstraZeneca Wins FDA Accelerated Approval for Ultomiris in IgA Nephropathy

AstraZeneca has received FDA accelerated approval for Ultomiris in adults with IgA nephropathy, based on an interim analysis showing a 43.4% reduction in proteinuria versus placebo at 34 weeks. The trial continues to 106 weeks to assess whether the drug slows loss of kidney function, which would support full approval.